File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Src kinase pathway is a potential candidate for molecular targeted therapy of non-small cell lung cancers (NSCLC) that show exon 19 deletion mutation or other epidermal growth factor receptor (EGFR) abnormalities

TitleSrc kinase pathway is a potential candidate for molecular targeted therapy of non-small cell lung cancers (NSCLC) that show exon 19 deletion mutation or other epidermal growth factor receptor (EGFR) abnormalities
Authors
Issue Date2007
PublisherAmerican Association for Cancer Research.
Citation
The 98th Annual Meeting of the American Association for Cancer Research (AACR 2007), Los Angeles, CA., 14-18 April 2007. In Cancer Research, 2007, v. 67 n. 9S, abstract no. 3769 How to Cite?
AbstractMolecular targeted therapy using tyrosine kinase inhibitors (TKI) against EGFR is an effective therapy for NSCLC that harbor EGFR mutations. However, tumour resistance due to second EGFR mutations or unknown mechanisms is frequently observed. Src kinase is known to interact with and mutually activate EGFR. The effect of src kinase inhibition on NSCLC has not been fully studied. 4-(4’-Phenoxyanilino)-6,7-dimethoxyquinazolinee (SKI-1) is a novel, potent and highly specific Src kinase inhibitor due to its simultaneous interaction with both the ATP- and peptide-binding sites. To assess the potential usefulness of Src kinase inhibition in treating NSCLC, we studied the effect of SKI-1 on apoptosis and changes in Src kinase and EGFR activation profiles in different NSCLC cells that harbor EGFR wild type (WT) (H358, H1819) or exon 19 deletion mutation (MT) (HCC827). Hoechst 33258 nuclear staining showed that SKI-1 significantly induced apoptosis in both H1819 and HCC827 but not H358 cells in a dose dependent manner. H358 and H1819 cells showed lower basal Src activities than HCC827 cells by immunoblot analysis against phosphorylated Y416. EGFR phosphorylation profiles were also different in the SKI-1 sensitive H1819 and HCC827 cells. While both showed inhibition of phosphorylation at Y416 of Src and Y845 of EGFR in a dose dependent manner, inhibition of EGFR phosphorylation at tyrosine 1068 and 992 was only observed in HCC827 but not H1819 cells. The lack of apoptosis in H358 and sensitivity of HCC827 cells to SKI treatment are consistent with previously reported observations that NSCLC cells harboring WT or MT-EGFR, respectively, show differential sensitivities to SKI due to enhancement of basal src kinase activation by MT EGFR. The inhibition of phosphorylation activation of EGFR at Y845 implicates that induction of apoptosis and sensitivity of HCC827 to SKI treatment is in part related to the involvement of Stat 3/5 pathway downstream of Y845 and, additional, such as the Akt, pathways downstream of EGFR Y1068 and Y992. In view of the WT EGFR and lower basal src kinase activity in H1819, its apoptotic response and sensitivity to SKI-induced inhibition of phosphorylation activation at Src Y416 and EGFR Y845 is unusual. One possible explanation could be related to the high EGFR copy number and expression levels of other ErbB family members in H1819. Overall, the findings indicate that the Src kinase pathway could be a useful target for the treatment of NSCLC. We further suggest that EGFR mutation and basal Src kinase activity are not the only factors that determine SKI sensitivity, but that other forms of abnormalities in EGFR and related family members may also be important determinants.
Persistent Identifierhttp://hdl.handle.net/10722/104639
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorLeung, LHen_HK
dc.contributor.authorChung, LPen_HK
dc.contributor.authorTam, Ien_HK
dc.contributor.authorTin. P-
dc.contributor.authorWong, MP-
dc.date.accessioned2010-09-25T22:01:19Z-
dc.date.available2010-09-25T22:01:19Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 98th Annual Meeting of the American Association for Cancer Research (AACR 2007), Los Angeles, CA., 14-18 April 2007. In Cancer Research, 2007, v. 67 n. 9S, abstract no. 3769-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/104639-
dc.description.abstractMolecular targeted therapy using tyrosine kinase inhibitors (TKI) against EGFR is an effective therapy for NSCLC that harbor EGFR mutations. However, tumour resistance due to second EGFR mutations or unknown mechanisms is frequently observed. Src kinase is known to interact with and mutually activate EGFR. The effect of src kinase inhibition on NSCLC has not been fully studied. 4-(4’-Phenoxyanilino)-6,7-dimethoxyquinazolinee (SKI-1) is a novel, potent and highly specific Src kinase inhibitor due to its simultaneous interaction with both the ATP- and peptide-binding sites. To assess the potential usefulness of Src kinase inhibition in treating NSCLC, we studied the effect of SKI-1 on apoptosis and changes in Src kinase and EGFR activation profiles in different NSCLC cells that harbor EGFR wild type (WT) (H358, H1819) or exon 19 deletion mutation (MT) (HCC827). Hoechst 33258 nuclear staining showed that SKI-1 significantly induced apoptosis in both H1819 and HCC827 but not H358 cells in a dose dependent manner. H358 and H1819 cells showed lower basal Src activities than HCC827 cells by immunoblot analysis against phosphorylated Y416. EGFR phosphorylation profiles were also different in the SKI-1 sensitive H1819 and HCC827 cells. While both showed inhibition of phosphorylation at Y416 of Src and Y845 of EGFR in a dose dependent manner, inhibition of EGFR phosphorylation at tyrosine 1068 and 992 was only observed in HCC827 but not H1819 cells. The lack of apoptosis in H358 and sensitivity of HCC827 cells to SKI treatment are consistent with previously reported observations that NSCLC cells harboring WT or MT-EGFR, respectively, show differential sensitivities to SKI due to enhancement of basal src kinase activation by MT EGFR. The inhibition of phosphorylation activation of EGFR at Y845 implicates that induction of apoptosis and sensitivity of HCC827 to SKI treatment is in part related to the involvement of Stat 3/5 pathway downstream of Y845 and, additional, such as the Akt, pathways downstream of EGFR Y1068 and Y992. In view of the WT EGFR and lower basal src kinase activity in H1819, its apoptotic response and sensitivity to SKI-induced inhibition of phosphorylation activation at Src Y416 and EGFR Y845 is unusual. One possible explanation could be related to the high EGFR copy number and expression levels of other ErbB family members in H1819. Overall, the findings indicate that the Src kinase pathway could be a useful target for the treatment of NSCLC. We further suggest that EGFR mutation and basal Src kinase activity are not the only factors that determine SKI sensitivity, but that other forms of abnormalities in EGFR and related family members may also be important determinants.-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research.-
dc.relation.ispartofCancer Researchen_HK
dc.titleSrc kinase pathway is a potential candidate for molecular targeted therapy of non-small cell lung cancers (NSCLC) that show exon 19 deletion mutation or other epidermal growth factor receptor (EGFR) abnormalitiesen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLeung, LH: laihanl@yahoo.comen_HK
dc.identifier.emailChung, LP: lpchung@hkucc.hku.hken_HK
dc.identifier.emailWong, MP: mwpik@hkucc.hku.hken_HK
dc.identifier.authorityChung, LP=rp00249en_HK
dc.identifier.authorityWong, MP=rp00348en_HK
dc.identifier.hkuros136133en_HK
dc.identifier.volume67-
dc.identifier.issue9 suppl.-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats